pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2008-0-6-84-89pulmo-1881Research ArticleОБЗОРЫREVIEWОбоснование многообразия противоаллергического действия обратных агонистов Н1-рецепторовA basis of multiple antiallergic effects of inverse H1-receptor agonistsГущинИ. С.GushchinI. S.
Москва
ГНЦ "Институт иммунологии ФМБА России"Russian Federation200828122008068489Copyright © Гущин И.С., 20082008Гущин И.С.Gushchin I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1881
.
.
ReferencesГущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт; 1998.Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус Принт; 1998.Гущин И.С. Антагонисты Н1-рецепторов как противо-аллергические лекарственные средства (обзор). Тер. арх. 1997; 10: 27–34.Гущин И.С. Антагонисты Н1-рецепторов как противо-аллергические лекарственные средства (обзор). Тер. арх. 1997; 10: 27–34.Гущин И.С. Антигистаминные препараты как высвободители гистамина и ингибиторы его высвобождения. В кн.: Патогенез аллергических процессов в эксперименте и клинике. М.: Медицина; 1979. 118–131.Гущин И.С. Антигистаминные препараты как высвободители гистамина и ингибиторы его высвобождения. В кн.: Патогенез аллергических процессов в эксперименте и клинике. М.: Медицина; 1979. 118–131.Гущин И.С., Зебрев А.И., Читаева В.Г. и др. Полифункциональные антиаллергические соединения, сочетающие антигистаминную активность со стабилизацией тучных клеток. Хим. фарм. журн. 1987; 11: 1313–1317.Гущин И.С., Зебрев А.И., Читаева В.Г. и др. Полифункциональные антиаллергические соединения, сочетающие антигистаминную активность со стабилизацией тучных клеток. Хим. фарм. журн. 1987; 11: 1313–1317.Simons F.E.R., ed. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, Inc.; 1996.Simons F.E.R., ed. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker, Inc.; 1996.Gether U. Uncovering molecular mechanisms involved in activation of G-protein coupled receptors. Endocr. Rev. 2000; 21: 90–113.Gether U. Uncovering molecular mechanisms involved in activation of G-protein coupled receptors. Endocr. Rev. 2000; 21: 90–113.Le Coniat M., Traifford E., Ruat M. et al. Chromosomal localization of the human histamine H1-receptor gene. Hum. Genet. 1996; 94: 186–188.Le Coniat M., Traifford E., Ruat M. et al. Chromosomal localization of the human histamine H1-receptor gene. Hum. Genet. 1996; 94: 186–188.Kuhn B., Schmid A., Harteneck C. et al. G proteins of the Gq family couple the H 2 histamine receptor to phospholipase C. Mol. Endocrinol. 1996; 10: 1697–1707.Kuhn B., Schmid A., Harteneck C. et al. G proteins of the Gq family couple the H 2 histamine receptor to phospholipase C. Mol. Endocrinol. 1996; 10: 1697–1707.Bakker R.A., Schoonus S.B.J., Smit M.J. et al. Histamine H1-receptor activation of nuclear factor κB: roles for Gβγ and Gαq/11 subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 2001; 60: 1133–1142.Bakker R.A., Schoonus S.B.J., Smit M.J. et al. Histamine H1-receptor activation of nuclear factor κB: roles for Gβγ and Gαq/11 subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 2001; 60: 1133–1142.Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867–6874.Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867–6874.Hu O., Deshpande S., Irani K. et al. [Ca2+ ]i oscillation frequency regulates agonist stimulated NF-κB transcriptional activity. J. Biol. Chem. 1999; 274: 33995–33998.Hu O., Deshpande S., Irani K. et al. [Ca2+ ]i oscillation frequency regulates agonist stimulated NF-κB transcriptional activity. J. Biol. Chem. 1999; 274: 33995–33998.Hart L.A., Krishnan V.L., Adcock I.M. et al. Activation and localization of transcription factor, nuclear factor κB, in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 1585–1592.Hart L.A., Krishnan V.L., Adcock I.M. et al. Activation and localization of transcription factor, nuclear factor κB, in asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 1585–1592.Desmet C., Gosset P., Pajak B. et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 2004; 173: 5766–5775.Desmet C., Gosset P., Pajak B. et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 2004; 173: 5766–5775.Poynter M.E., Cloots R., Van Woerkom T. NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness. J. Immunol. 2004; 173: 7003–7009.Poynter M.E., Cloots R., Van Woerkom T. NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness. J. Immunol. 2004; 173: 7003–7009.Catley M.C., Chivers J.E., Holden N.S. et al. Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br. J. Pharmacol. 2005; 145: 114–122.Catley M.C., Chivers J.E., Holden N.S. et al. Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br. J. Pharmacol. 2005; 145: 114–122.Bakkouri E.L., Wullaert A., Haegman M. et al. Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J. Biol. Chem. 2005; 280: 17938–17944.Bakkouri E.L., Wullaert A., Haegman M. et al. Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J. Biol. Chem. 2005; 280: 17938–17944.Na H.J., Moon P.D., Ko S.G. et al. Sargassum hemiphyllum inhibits atopic allergic reaction via the regulation of inflammatory mediators. J. Pharmacol. Sci. 2005; 97: 219–226.Na H.J., Moon P.D., Ko S.G. et al. Sargassum hemiphyllum inhibits atopic allergic reaction via the regulation of inflammatory mediators. J. Pharmacol. Sci. 2005; 97: 219–226.Peng Y., Power M.R., Li B., Lin T.J. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB path way in IgE-dependent mast cell activation. J. Leukoc. Biol. 2005; 77: 975–983.Peng Y., Power M.R., Li B., Lin T.J. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB path way in IgE-dependent mast cell activation. J. Leukoc. Biol. 2005; 77: 975–983.Caramori G., Adcock I.M., Ito K. Antiinflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr. Opin. Invest. Drugs 2004; 5: 1141–1147.Caramori G., Adcock I.M., Ito K. Antiinflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr. Opin. Invest. Drugs 2004; 5: 1141–1147.Buddenkotte J., Stroh C., Engels I.H. et al. Agonists of proteinase-activated receptor 2 stimulate upregulation of intercellular cell adhesion molecule 1 in primary human keratinocytes via activation of NF-kappa B. J. Invest. Dermatol. 2005; 124: 38–45.Buddenkotte J., Stroh C., Engels I.H. et al. Agonists of proteinase-activated receptor 2 stimulate upregulation of intercellular cell adhesion molecule 1 in primary human keratinocytes via activation of NF-kappa B. J. Invest. Dermatol. 2005; 124: 38–45.Asano K., Kanai K.I., Suzaki H. Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin. Exp. Allergy 2004; 34: 1890–1898.Asano K., Kanai K.I., Suzaki H. Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin. Exp. Allergy 2004; 34: 1890–1898.Edwards M.R., Mukaida N., Johnson M., Johnston S.L. IL-1 beta induces IL-8 in bronchial cells via NF-kappaB and NF-IL6 transcription factors and can be suppressed by glucocorticoids. Pulm. Pharmacol. Ther. 2005; 18: 337–345.Edwards M.R., Mukaida N., Johnson M., Johnston S.L. IL-1 beta induces IL-8 in bronchial cells via NF-kappaB and NF-IL6 transcription factors and can be suppressed by glucocorticoids. Pulm. Pharmacol. Ther. 2005; 18: 337–345.Chowdhury B.A., Kaliner M.A. Molecular identification of the H1 receptor in humans. In: Simons F.E.R., ed. Histamine and H1 receptor antagonists in allergic disease. New York: Marcel Dekker, Inc.; 1996. 33–60.Chowdhury B.A., Kaliner M.A. Molecular identification of the H1 receptor in humans. In: Simons F.E.R., ed. Histamine and H1 receptor antagonists in allergic disease. New York: Marcel Dekker, Inc.; 1996. 33–60.Bruysters M., Jongejan A., Gillard M. et al. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84(2.61) as key residue within an additional binding pocket in the H 1 receptor. Mol. Pharmacol. 2005; 67: 1045–1052.Bruysters M., Jongejan A., Gillard M. et al. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84(2.61) as key residue within an additional binding pocket in the H 1 receptor. Mol. Pharmacol. 2005; 67: 1045–1052.Church M. Histamine receptors, inverse agonism, and allergy. J. Wld Allergy Org. 2004; 16: 112–116.Church M. Histamine receptors, inverse agonism, and allergy. J. Wld Allergy Org. 2004; 16: 112–116.Leurs R., Church M.K., Taglialatela M. H1 antihistamines: inverse agonism, antiinflammatory actions and cardiac effects. Clin. Exp. Allergy 2002; 32: 489–498.Leurs R., Church M.K., Taglialatela M. H1 antihistamines: inverse agonism, antiinflammatory actions and cardiac effects. Clin. Exp. Allergy 2002; 32: 489–498.Bakker R.A., Wieland K., Timmerman H., Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur. J. Pharmacol. 2000; 387: R5–R7.Bakker R.A., Wieland K., Timmerman H., Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur. J. Pharmacol. 2000; 387: R5–R7.Govoni M., Bakker R.A., van de Wetering I. et al. Synthesis and pharmacological identification of neutral histamine H1 receptor antagonists. J. Med. Chem. 2003; 46: 5812–5824.Govoni M., Bakker R.A., van de Wetering I. et al. Synthesis and pharmacological identification of neutral histamine H1 receptor antagonists. J. Med. Chem. 2003; 46: 5812–5824.Гущин И.С. Спонтанная ("конститутивная") активность и обратный агонизм на Н1 рецепторах. Рос. аллергол. журн. 2006; 2: 3–14.Гущин И.С. Спонтанная ("конститутивная") активность и обратный агонизм на Н1 рецепторах. Рос. аллергол. журн. 2006; 2: 3–14.Gillard M., Strolin Benedetti M., Chatelain P., Baltes E. Histamine H 1 receptor occupancy and pharmacodynamics of second generation H1 antihistamines. Inflamm. Res. 2005; 54: 367–369.Gillard M., Strolin Benedetti M., Chatelain P., Baltes E. Histamine H 1 receptor occupancy and pharmacodynamics of second generation H1 antihistamines. Inflamm. Res. 2005; 54: 367–369.del Cuvillo A., Millol J., Bartra J. et al. Comparative pharmacology of H 1 antihistamines. J. Invest. Allergol. Clin. Immunol. 2006; 16 (suppl. 1): 3–12.del Cuvillo A., Millol J., Bartra J. et al. Comparative pharmacology of H 1 antihistamines. J. Invest. Allergol. Clin. Immunol. 2006; 16 (suppl. 1): 3–12.Warner J.O., ETAC Study Group. A double blind, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow up. J. Allergy Clin. Immunol. 2001; 108: 929–937.Warner J.O., ETAC Study Group. A double blind, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow up. J. Allergy Clin. Immunol. 2001; 108: 929–937.Simons F.E.R. on behalf of the Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18 month study. Pediatr.Allergy Immunol. 2007; 18: 535–542.Simons F.E.R. on behalf of the Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18 month study. Pediatr.Allergy Immunol. 2007; 18: 535–542.
The authors declare that there are no conflicts of interest present.